Influenza antivirals and their role in pandemic preparedness.
Antiviral Res
; 210: 105499, 2023 Feb.
Article
in English
| MEDLINE | ID: covidwho-2237812
ABSTRACT
Effective antivirals provide crucial benefits during the early phase of an influenza pandemic, when vaccines are still being developed and manufactured. Currently, two classes of viral protein-targeting drugs, neuraminidase inhibitors and polymerase inhibitors, are approved for influenza treatment and post-exposure prophylaxis. Resistance to both classes has been documented, highlighting the need to develop novel antiviral options that may include both viral and host-targeted inhibitors. Such efforts will form the basis of management of seasonal influenza infections and of strategic planning for future influenza pandemics. This review focuses on the two classes of approved antivirals, their drawbacks, and ongoing work to characterize novel agents or combination therapy approaches to address these shortcomings. The importance of these topics in the ongoing process of influenza pandemic planning is also discussed.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Influenza, Human
Type of study:
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Antiviral Res
Year:
2023
Document Type:
Article
Affiliation country:
J.antiviral.2022.105499
Similar
MEDLINE
...
LILACS
LIS